Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alnespirone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.98 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alnespirone SCHEMBL29349572 | 1.00 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL29390957 | 1.00 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL29639699 | 0.99 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL13532499 | 0.99 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| Alnespirone SCHEMBL114478 | 0.99 | HTR1A (1.00) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL13532497 | 0.98 | HTR1A (0.98) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL13532501 | 0.93 | HTR1A (0.89) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9306008 | 0.90 | HTR1A (0.83) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL13532502 | 0.89 | HTR1A (0.81) | HTR1ADRD2DRD1HTR1BHTR2A | |
| SCHEMBL9304956 | 0.89 | HTR1A (0.81) | HTR1ADRD2DRD1HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1078 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447949-A1 | PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME | Neurawell Therapeutics (US) | 2024-10-23 | — | — | EP | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| WO-2023114453-A1 | PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME | Neurawell Therapeutics (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2022165382-A1 | PHENYLETHYLIDENEHYDRAZINE COMBINATION THERAPIES | Neurawell Therapeutics (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220062279-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA A/S (DK) | 2022-03-03 | — | — | US | claimed |
| EP-3897641-A1 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma A/S (DK) | 2021-10-27 | — | — | EP | claimed |
| WO-2020127954-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2020-06-25 | — | — | WO | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| CN-108853506-A | A kind of combination drug and application thereof for treating leukaemia | 四川科瑞德制药股份有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-1418100-A | Compounds with 5-HT activity for controlling visual field loss | ALCON UNIVERSAL LTD (CH) | 2003-05-14 | — | — | CN | claimed |
| CN-1418121-A | Compound with 5-HT1A activity useful for treating disorders of outer retina | ALCON UNIVERSAL LTD (CH) | 2003-05-14 | — | — | CN | claimed |
| EP-1267878-A2 | COMPOUNDS WITH 5-HT ACTIVITY USEFUL FOR CONTROLLING VISUAL FIELD LOSS | Alcon, Inc (CH) | 2003-01-02 | — | — | EP | claimed |
| EP-1263504-A2 | COMPOUNDS WITH 5-HT1A ACTIVITY USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA | Alcon Inc. (CH) | 2002-12-11 | — | — | EP | claimed |
| EP-1259292-A2 | THERAPEUTIC AGENTS | Knoll GmbH (DE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001070222-A2 | COMPOUNDS WITH 5-HT1A ACTIVITY USEFUL FOR TREATING DISORDERS OF THE OUTER RETINA | ALCON INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| WO-2001070230-A2 | COMPOUNDS WITH 5-HT ACTIVITY USEFUL FOR CONTROLLING VISUAL FIELD LOSS | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062341-A2 | COMBINATION PRODUCT FOR THE TREATMENT OF OBESITY | KNOLL GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HTR1A 91/4885DRD2 186/4885DRD1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.